Filing Flows › Pelthos Therapeutics (PTHS) › R&D spending
Pelthos Therapeutics (PTHS) R&D spending by quarter
Pelthos Therapeutics' R&D spending was $600K in Q2 2026 (second quarter 2026), +223% from Q1 2026. Over the last 4 quarters it ranged from $145K (Q3 2025) to $600K (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $600K | +223% | — |
| Q1 2026 | $186K | -50% | — |
| Q4 2025 | $374K | +158% | — |
| Q3 2025 | $145K | — | — |
Q2 2026 at a glance
Pelthos Therapeutics, Q2 2026: revenue $15.6M, operating margin -111.0%, net loss $23.4M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Pelthos Therapeutics' R&D spending?
Pelthos Therapeutics' R&D spending was $600K in Q2 2026 (second quarter 2026), +223% from Q1 2026.
How has Pelthos Therapeutics' R&D spending changed?
Over the last 4 quarters it ranged from $145K (Q3 2025) to $600K (Q2 2026).